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Conformational dynamics of α-synuclein: insights
from mass spectrometry†
Ashley S. Phillips,a Alexandre F. Gomes,b Jason M. D. Kalapothakis,c Jay E. Gillam,c
Jonas Gasparavicius,d Fabio C. Gozzo,b Tilo Kunath,e Cait MacPheec and
Perdita E. Barran*a
The aggregation and deposition of α-synuclein in Lewy bodies is associated with the progression of
Parkinson’s disease. Here, Mass Spectrometry (MS) is used in combination with Ion Mobility (IM), chemical
crosslinking and Electron Capture Dissociation (ECD) to probe transient structural elements of α-synuclein
and its oligomers. Each of these reveals diﬀerent aspects of the conformational heterogeneity of this
14 kDa protein. IM-MS analysis indicates that this protein is highly disordered, presenting in positive ionis-
ation mode with a charge state range of 5 ≤ z ≤ 21 for the monomer, along with a collision cross section
range of ∼1600 Å2. Chemical crosslinking applied in conjunction with IM-MS captures solution phase
conformational families enabling comparison with those exhibited in the gas phase. Crosslinking IM-MS
identiﬁes 3 distinct conformational families, Compact (∼1200 Å2), Extended (∼1500 Å2) and Unfolded
(∼2350 Å2) which correlate with those observed in solution. ECD-Fourier Transform-Ion Cyclotron
Resonance Mass Spectrometry (ECD-FT-ICR MS) highlights the eﬀect of pH on α-synuclein structure,
identifying the conformational ﬂexibility of the N and C termini as well as providing evidence for structure
in the core and at times the C terminus. A hypothesis is proposed for the variability displayed in the struc-
tural rearrangement of α-synuclein following changes in solution pH. Following a 120 h aggregation time
course, we observe an increase in the ratio of dimer to monomer, but no gross conformational changes
in either, beyond the signiﬁcant variations that are observed day-to-day from this conformationally
dynamic protein.
Introduction
Mass Spectrometry (MS) and the hybrid technique, Ion Mobi-
lity Mass Spectrometry (IM-MS) have emerged as useful tools
to investigate the early stages of aggregation of proteins impli-
cated in protein misfolding diseases, and the multiple confor-
mational families that co-exist during the process.1 IM-MS can
be used to measure heterogeneous samples (both in terms of
stoichiometry and conformation), requires a low sample
volume and allows a relatively short transfer time from bench
to instrument. There are diﬀerent forms of ion mobility instru-
ments, however in this work we use drift tube based measure-
ments (DT-IM-MS). DT-IM-MS has been described in detail
elsewhere,2 but briefly, it is an analytical technique that
measures the time it takes a given m/z selected ion to pass
through a drift cell filled with an inert buﬀer gas, under the
influence of a weak electrostatic field. Under low field con-
ditions, injected ions drift through the drift cell and are
retarded as well as thermalized by collisions with the buﬀer
gas. The mobility of an ion (K) is defined as the ratio between
the drift velocity (vd), which is measured by measuring the
arrival time and the applied electric field (E), and then convert-
ing to the reduced mobility (K0) by normalising the tempera-
ture and pressure of the drift gas. The mobility of any given
ion is related to its rotationally averaged Collision Cross
Section (CCS) (Ω) according to the Mason-Schamp equation3
where N is the number gas density, μ is the reduced mass of
the ion and the buﬀer gas, and z is the charge on the ion.
K0 ¼ 3ze16N
2π
μkBT
 0:5 1
Ω
ð1Þ
The aggregation of and the pre-fibrillar aggregates formed
by β-2-microglobulin has been studied using IM-MS
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approaches by the Vachet,4 Radford5,6 and Ashcroft groups.7–10
Bowers and co-workers have extensively studied amyloid-β11–16
with contributions from Robinson.17 Other work has examined
amylin,18–24 Tau25 and a peptide from the amyloid disease
associated protein Transthyretin or TTR.26 These constitute
several of the 30 diﬀerent proteins which have been implicated
as causal factors in human disease due to their inability to
adopt or remain in their native conformational state.27 Such
diseases are referred to as protein misfolding diseases due to
the change in shape of the precursor protein, and most neuro-
degenerative diseases fall into this category. The mechanism
of dysfunction varies however, a common identifier is that nor-
mally soluble proteins form organised, insoluble fibrillar and
oligomeric aggregates.27 Parkinsons Disease (PD) is one of
these diseases and the protein involved is α-synuclein, a major
constituent of the characteristic Lewy bodies, where it presents
in an organised fibrillar state.28,29
α-synuclein is a member of a subset of proteins known as,
intrinsically disordered proteins (IDPs), defined as lacking (or
having regions lacking) tertiary fold observable on the time-
scale of an NMR experiment. α-synuclein is a 140 amino acid
protein encoded by a single gene, SNCA and in neurons it is
localised predominantly in the presynaptic nerve terminals
and nucleus.30 The exact function of α-synuclein is unknown
however, it is theorised to be involved in synaptic function and
neurotransmitter release.31 There is a large body of evidence
indicating that α-synuclein exists as an unstructured monomer
under a range of biophysical assays31–34 and even in cells.35
However, the α-synuclein found in Lewy bodies has condensed
to fibrillar aggregates rich in β-sheet structure. The aggregation
pathway has been described as containing multiple inter-
mediate oligomer structures including spherical36 and ring-
shaped31,37 forms and is susceptible to pertubation, through
changes to environmental factors. These factors include agita-
tion, temperature and pH.38 The transition from native confor-
mation to these amyloid deposits is therefore not a single step,
nor a single pathway, and hence in order to understand the
mechanisms at play it is critical to identify the species
present at each step. Oligomers formed in the early stages of
aggregation are most applicable as drug targets since they
are reported to be the most toxic species that mediate
neurodegeneration.7,39
The Bowers,40 Kaltashov41 and Grandori42 have previously
demonstrated the conformational plasticity of α-synuclein
using mass spectrometry based approaches. All groups have
reported the presence of multiple co-existing α-synuclein
conformers under native conditions, including tightly
folded and extended conformers.40–42 These studies have
demonstrated the importance of solution conditions on the
conformers presented by α-synuclein, in particular pH
dependence. Bernstein et al. and Frimpong et al. indepen-
dently reported a shift to lower charged, more compact
species at low pH,40,41 whereas Natalello et al. showed a shift
to higher charged, more extended conformers at basic pH.42
Bernstein et al. also noted the presence of dimer species at pH
2.5 and their absence at pH 7.40 In comparison, Frimpong
et al. described the presence of dimer species at pH 2.5 to pH
8. The selective stabilisation of α-synuclein conformers via
diﬀerent alcohols has also been displayed via MS.41,42 Taking
the data of these studies alone, it is clear that α-synuclein is
extremely susceptible to environmental perturbations and
even under tightly controlled conditions, significant variation
in the data produced occurs.
MS approaches have also been applied to study other
aspects of α-synuclein for example to study the eﬀect of frag-
ments on aggregation43,44 and to characterise the influence of
metal ion binding, on conformation and aggregation.42,45–47
MS has been used to examine post-translational modifications
in α-synuclein, identifying phosphorylated species in CSF48
and to investigate the eﬀect of such post translational modifi-
cations on the behaviour of α-synuclein.49,50 Naturally occur-
ring in vivo crosslinking of α-synuclein has been investigated
with MS and implicated as both inducing and preventing
aggregation.51,52 Photo-induced crosslinking of α-synuclein
in vitro has been used to probe the properties and cellular tox-
icity of oligomers and the di-tyrosine cross links were identi-
fied with mass spectral analysis.53
Hydrogen-Deuterium Exchange (HDX) can be used in con-
junction with MS to monitor protein conformational
dynamics54,55 and has been applied to the study of monomeric
and low order oligomeric species of α-synuclein.56–59 These
studies have confirmed that the α-synuclein monomer is an
unstructured solvent accessible protein, as a result of the rapid
exchange which is seen across the entire sequence length.56,57
Following the induction of an amyloid state, HDX has helped
uncover structural changes experienced by α-synuclein,56,58 but
apparent inconsistencies in results from diﬀerent groups high-
lights the dynamic nature of α-synuclein. Furthermore HDX
has also allowed the designation of two distinct oligomers
with diﬀerent levels of protection, which may represent the
intermediates of two diﬀerent aggregation pathways.59 HDXs
ability to define structural information is backed by evidence
from Lee et al., whose work on the binding of α-synuclein to
lipids, highlights regions of protection in the N terminus,
which correlates with the induction of α-helical structure in
the α-synuclein N terminus following binding to a SLAS
micelle, described previously.57,60
MS has also enabled the study of the binding interactions
of α-synuclein with a number of ligands including potential
drug candidates, and in vivo partners,61,62 including sper-
mine,63 and dopamine.64 In this study MS and IM-MS are
applied; to investigate the conformational plasticity of α-synu-
clein, to detect low order oligomeric species and to follow the
early stages of aggregation. In vitro chemical crosslinking is
used here in conjunction with IM-MS to capture transient con-
formational populations of monomeric α-synuclein. ECD-
FT-ICR MS is also applied to investigate the structure of
monomeric and dimeric species from diﬀerent solution con-
ditions. Our data is compared to data reported in previous
studies. We use transmission electron microscopy to deter-
mine fibril formation under the solution conditions employed
in MS studies.
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Experimental methods and materials
Materials
AR grade ammonium acetate, sodium phosphate, was pur-
chased from Fisher Scientific (Loughborough, UK). BS3 cross-
linker, sodium carbonate, sodium acetate, HEPES, potassium
hydroxide and acetic acid were purchased from Sigma Aldrich
(UK). Water was purified with an Arium 611 water purification
system (Sartorius, Göttingen, Germany).
α-synuclein preparation
α-synuclein was expressed recombinantly, from a pT7–7 vector
containing human α-synuclein gene, kindly provided by
Dr Jean-Christophe Rochet, Purdue University and purified as
described previously;65 a Resource Q column (GE Healthcare
Life Sciences, UK) was used. α-synuclein used for crosslinking,
IM-MS and ECD-FT-ICR-MS analysis, was purified as
described, concentrated using Vivaspin 6 centrifugal sample
concentrators (MWCO 10 kDa) (GE Healthcare Life Sciences,
UK) and applied to a HiPrep 26/10 desalting column (GE
Healthcare Life Sciences, UK) pre-equilibrated with 100 mM
ammonium acetate, flow rate 10 mL min−1. The eluent was lyo-
philised and stored at −80 °C prior to use. Prior to analysis, if
required, samples were thawed and dialysed into a 50 mM
ammonium acetate buﬀer solution (pH 7) overnight at 4 °C
using 3.5 kDa MWCO Slide-A-Lyzer Dialysis cassettes (Thermo
Scientific, USA). Post-dialysis concentration was determined by
a BCA assay (Pierce, Thermo Scientific, USA) prior to aliquoting.
Aggregation procedure
α-synuclein (70 μM, 50 mM ammonium acetate, pH 7) was
incubated at 37 °C with agitation at 200 rpm in an incubator
shaker, a method adapted from the work of Hashimoto et al.
and Fink et al.66,67 Samples were incubated individually and at
specified time points were removed and analysed immediately.
The time taken to transfer the sample from incubation to
nano-spraying tip was never more than 3 minutes. The
samples were incubated for up to 120 hours and analysed at
t = 0, 24, 48, 72, 96 and 120 hours.
Crosslinking procedure
For α-synuclein crosslinking experiments, the conditions were
based on the manufacturers recommended conditions and the
previously published work of Chen et al.68 and primarily, Igle-
sias et al.69 Here, four buﬀer conditions, each at 50 mM,
sodium acetate (pH 4), sodium phosphate (pH 6), HEPES (pH
8) and sodium carbonate (pH 10) were used. The pH of the
HEPES buﬀer was modified with KOH. Since each crosslinking
reagent has optimal operating conditions in terms of pH for
maximum reactivity, by altering the pH during the crosslinker
incubation, we are able to modulate the number of modifi-
cations. Lyophilised α-synuclein was reconstituted in each
buﬀer solution to which BS3 at 50 : 1 molar excess was added,
final α-synuclein concentration, 100 μM. Crosslinking reac-
tions were incubated at room temperature for 1 hour. Reac-
tions were quenched by the addition of 1 M ammonium
acetate. Samples were desalted via buﬀer exchange into 50 mM
ammonium acetate (pH 6.8) using Amicon Ultra centrifuge
filters, MWCO 10 kDa (Millipore).
Nano-Electrospray Ionisation (nESI) was used for all MS
and IMMS experiments, with the exception of ECD-FT-ICR MS.
nESI tips were fabricated in-house using thin wall capillaries
(ID 0.9 mm) (World Precision Instruments, Inc, USA) using a
Fleming/Brown micropipette puller (Sutter Instruments Co.,
USA). Samples were ionised via the insertion of platinum wire
into the nESI tip to which a voltage was applied.
Mass spectrometry
MS experiments were conducted on an Ultima API-US instru-
ment (Micromass, Manchester, UK). Desalted α-synuclein was
diluted with 50 mM ammonium acetate to a concentration of
70 μM. MS was conducted in positive mode. Source conditions
were kept as similar as possible to enable comparison: capil-
lary voltage ∼1.6 kV, cone voltage 165 V and source tempera-
ture 80 °C. For pH variation experiments, the solution pH was
modified by the addition of acetic acid.
Drift Tube Ion Mobility Mass Spectrometry (DT-IM-MS)
Drift Time Ion Mobility Mass Spectrometry measurements
were performed on an in-house modified Q-ToF instrument
(Micromass, Manchester, UK). The instrument has been modi-
fied via the addition of a 5.1 cm long copper drift cell and
additional post source ion optics to carry out gas phase separ-
ation of protein ions based on the ion mobility, further instru-
ment specifics are detailed elsewhere.70 Each experiment in
the time course was performed in triplicate. Measurements
were made at eight diﬀerent drift voltages between 60 V and
10 V. For aggregation and crosslinking IM-MS experiments,
tuning conditions were kept as similar as possible: capillary
voltage ∼1.6 kV, cone voltage ∼98 V and source temperature
80 °C. The temperature and pressure of helium in the drift cell
were on average: 302.4 K and 3.8 Torr, respectively, but are
recorded and used to calculate mobilities for each experiment.
Ion arrival time distributions (ATD) are recorded by syn-
chronising the entry of each ion pulse into the drift cell with
mass spectral acquisition. The mobility of the ion of interest
was obtained from a linear plot of the average arrival time
versus pressure/temperature, from which the rotationally-aver-
aged Collision Cross Section (CCS) for each resolvable species
at a given charge state was found using eqn (1). Collision Cross
Section Distributions (CCSD) were created by plotting the
average CCS against peak intensity values and charge. Data
analysis was conducted using Masslynx v4.1 (Waters Corpor-
ation, USA), Origin v8–9.5 (OriginLab Corporation, USA) and
Microsoft Excel (Microsoft, USA).
ECD-FT-ICR-MS
Lyophilised α-synuclein was reconstituted in 50 mM ammonium
acetate to a concentration of 30 μM. Samples were prepared at
pH 3.5 and pH 6.8. pH was adjusted by addition of acetic acid.
Protein samples were ionised and introduced to the mass
spectrometer using a Triversa Nanomate (Advion, New York,
Paper Analyst
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USA). Spectra were acquired with a Bruker Solarix 12 T FT-ICR
Mass Spectrometer (Bruker Daltronics, Bremen, Germany).
ECD-FT-ICR MS was performed after first acquiring a native
mass spectrum by tuning source optics. Specific ion species
were then isolated using the mass resolving quadrupole prior
to MS/MS via ECD. For ECD, 1.7 A was applied to the cathode
filament, 22 V to the lens, 1.2 V to the bias, and a pulse of
between 15 and 20 ms was employed. Fragmentation data is
the sum of 70 acquisitions. Data analysis was performed using
DataAnalysis (Bruker Daltronics, Bremen, Germany). The SNAP
2.0 algorithm was used for peak picking and the matching of
fragment peaks to calculated fragment masses was conducted
by Prosight PTM (v1.0).71
Results and discussion
Mass spectrometry experiments, contrasting day to day
variations, and the eﬀect of lowered pH with data from
aggregation time courses
Day to day variations. Here, MS has been used to diﬀeren-
tiate the inherent conformational flux of α-synuclein from the
eﬀects of diﬀerent nESI solution conditions.
Fig. 1A and B show MS spectra obtained from identically
prepared samples taken under highly similar source con-
ditions on the same instrument, approximately one month
apart. In each case the spectra are predominantly due to the
monomeric form of α-synuclein with a mass of 14 453 Da
(cf. theoretical average mass, 14 460 Da). Both spectra also
show evidence of higher order aggregates at low intensity.
Comparison of the two spectra demonstrates the aforemen-
tioned conformational flux as well as the diﬃculty in acquiring
reproducible data from this highly disordered protein. The
most obvious change is seen in the relative population of
diﬀerent charge states as well as the distribution between
monomer and higher order aggregates. In both cases, the protein
exhibits a wide CSD, Fig. 1B shows a CSD of 5 ≤ z ≤ 19 for the
monomeric species [aSyn + zH]z+, cf. a distribution of 5 ≤ z ≤ 20
in Fig. 1A. However, the most intense species in Fig. 1A is at z =
17 (m/z = 851.6) and in Fig. 1B is z = 14 (m/z = 1033.9). Other
diﬀerences in the relative intensities of ions can be observed: for
example the z = 10 ion (m/z = 1447) has significant intensity in
Fig. 1A but is weaker in 1B, and here the z = 11 species (m/z =
1315.5) is much more abundant. Fig. 1A has multimodal distri-
bution with at least three modes, z = 17, z = 14 and z = 11, by con-
trast, the data in Fig. 1B has a predominantly monomodal
distribution, centred on z = 14. Fig. 1B shows less intensity in
peaks assigned as dimeric species. This can be clearly identified
by comparison of the relative abundance of monomer and dimer
peaks of Fig. 1A and B and the less distinct multimodal distri-
bution of Fig. 1B. This change is accompanied by lowered inten-
sities of the observed trimeric and tetrameric species.
Fig. 1 Comparison of nESI-MS data of α-synuclein (1 mg mL−1) (50 mM ammonium acetate). A & B. α-synuclein pH 6.8, spectra taken under similar
instrumental and identical sample conditions. C. α-synuclein pH 3.5, D. α-synuclein pH 6.8 post-96 hour aggregation. N.b. the x-axis scale is
enlarged for C to reﬂect the lower charge states displayed. The y-axis scale is altered for D to enable comparison.
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This data suggests that the low order oligomeric species
identified (dimer to tetramer) vary in their presentation to the
gas phase. Such fluctuations in spectra are typical for this
protein following nano-ESI-MS analysis under similar experi-
mental conditions.
Change in pH. Fig. 1C shows the CSD obtained following
nESI-MS at pH 3.5. The drop in pH (cf. Fig. 1A and B) results
in a significant change in the way the protein presents in the
gas phase environment. Despite the increased availability of
protons, there is a dramatic decrease in the intensity of highly
charged monomeric species and an increase in the intensity of
lower charged species. This is evident when the width and the
relative position of CSDs are compared. The monomer CSD
shifts from 5 ≤ z ≤ 20 (Fig. 1A) to 3 ≤ z ≤ 12 (Fig. 1C) and pre-
sents in a multimodal CSD with populations centred on z = 10,
z = 7. This modification is even more evident upon comparison
of the dimeric species CSD, shifting from 10 ≤ z ≤ 23 (Fig. 1A)
to 7 ≤ z ≤ 13 (Fig. 1C). This eﬀect is seen for all multimeric
species.
This shift mirrors a change identified by Frimpong et al.
where solution pH was dropped to pH 2.5.41 Our findings
suggest that the protein has adopted a more compact struc-
ture, thereby decreasing solvent accessibility of protonatable
sites and leading to lower charge states prevailing. This corre-
lates with data from multiple physical techniques including
IR, SAXs72 and IM-MS,40 which demonstrate an induction of
structure72 and a partial collapse of the protein on lowering
pH,40 both changes which decrease solvent accessibility
and would decrease the average protonation state as
shown here (Fig. 1C).
The induction of structure by pH may contribute to the
increased detection of higher order species. The increase is
clearly seen via comparison of the tetramer species present, z =
29 (Fig. 1A) and 15 ≤ z ≤ 17 (Fig. 1C). The large increase in
baseline noise is attributable to an increase in higher ordered
aggregates.73 The low sample pH combined with the low pI of
α-synuclein (4.67), results in less protein–protein repulsion
and is therefore an environment conducive to oligomer for-
mation.34 This is supported by the depletion of the overall
signal intensity. A similar eﬀect is also seen under aggregating
conditions (ESI† Fig. S1).
MS following aggregation. Fig. 1D shows a mass spectrum
obtained following 96 hours of aggregation at neutral pH.
Initial comparison of Fig. 1A and B to data in Fig. 1D reveals
similarities, the width of the CSDs of monomer, dimer and
trimer species remain stable despite lengthy incubation under
aggregation inducing conditions.
The aggregation of α-synuclein is presumed to be a nuclea-
tion dependent process and it has been suggested that the
dimer is the aggregation nucleus.65,74 As mentioned previously
the dimer CSD remains similar to the t0 spectrum (Fig. 1A)
suggesting that the soluble population which must act as a
feeder stock for the aggregates is comprised of forms of the
protein that are conformationally dynamic, even when signifi-
cant aggregates are present. This is in contrast to earlier work
on aggregation of the peptide TTR (105–115)26 where at a mid-
point in the aggregation time course a significant increase in
the intensity of all observable higher order aggregates was
reported followed by a decrease in the late stages and the per-
sistence of dimer and tetramer species. However, it should be
noted that the data in all panels in Fig. 1 have been normal-
ised to the base peak, the absolute intensity of the species in
Fig. 1D are depleted by almost 50%, compared to the species
at t = 0. We speculate that this depletion is the result of low
order species being sequestered into much larger oligomers,
the presence of which is confirmed by TEM (ESI† Fig. S2)
suggesting that this data is taken at a late point in the aggrega-
tion time course. Such large fibrils are not detectable by MS in
this configuration. This depletion correlates with an increase
in baseline noise, also indicative of aggregation (as shown in
Fig. 1C) and as previously reported.26
By plotting of the ratio of the sum of the absolute intensity
of monomer and dimer peaks of the spectra at four time
points along the aggregation course, we observe a shift in ion
intensity to dimers with respect to time (Fig. 2). The intensity
of even charged dimer peaks will be aﬀected by the mass
coincident monomer peaks, although this will not signifi-
cantly aﬀect this qualitative analysis. The increase in
monomer intensity at 96 hours, is similar to the rise in
monomer intensity after 4 hours of aggregation of
TTR(105–115), which we theorised to be the result of the
destabilisation of higher order aggregates in the solution or
upon desolvation.26
IM-MS – following conformations through an aggregation time
course
The in vitro aggregation of α-synuclein was conducted as
described previously for up to 120 hours, and followed by
IM-MS. Collision Cross Section Distributions (CCSD) derived
from arrival time distributions for selected monomer and
dimer species are shown in Fig. 3 (See ESI† Fig. S3 for MS
spectra). At t = 0 for [aSyn + 6H]6+ a narrow CCSD centred on
∼1400 Å2 is observed with a small shoulder attributed to the
Fig. 2 A plot of the monomer: dimer ratio derived from the average
sum of the intensity of all monomer and dimer peaks of three indepen-
dent experiments following an aggregation time course.
Paper Analyst
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mass to charge coincident species [(aSyn)2 + 12H]
12+ (Fig. 3Ai).
The large error bars indicate these species are highly
variable and they are no longer present in subsequent
time point CCSDs for [aSyn + 6H]6+. At subsequent time
points the CCSD remains unchanged with the exception of the
loss of the shoulder, perhaps a result of sequestration to
higher order oligomeric species, the CCSD remains centred on
∼1400 Å2 (Fig. 3Aiii). For the higher charged monomeric
species, [aSyn + 10H]10+ the CCSD is much broader and
centred on ∼1800 Å2 (Fig. 3Bi). At subsequent time
points for the [aSyn + 10H]10+ CCSD, the majority of species
intensity remains centred on ∼1800 Å2. Additionally, a
shoulder is consistently present across all time points centred
on ∼2300 Å2 (Fig. 3Bi–iii).
In comparison to the data of Bernstein et al.40 despite the
fact that a diﬀerent ionisation mode has been used (negative
instead of positive as used here), the CCS values derived are in
good agreement for each charge state, although the Bernstein
data indicates the presence of an additional slightly larger con-
former. However, the CCS values derived for the [aSyn ± 10H]10±
species show a discrepancy. The Bernstein CCS value is
∼2500 Å2 (Fig. 4, ref. 40) whereas the major peak in our CCSD
plot is centred on ∼1800 Å2 (Fig. 3B). The lower intensity
shoulder centred at ∼2300 Å2, represents a more extended con-
former. This suggests that we have a cooler source, or we
observe a diﬀerence resulting from charge location. For
[aSyn + 13H]13+, the CCSD is broad and centred on ∼3000 Å2
(Fig. 3Ci). This CCSD also features a shoulder, attributed
a compact conformer. Again the large error bars are
consistent with a lowly populated species not present in sub-
sequent time points where the intensity remains centred on
∼3000 Å2 (Fig. 3Cii–iii).
Fig. 3 CCS distributions for the A: [aSyn + 6H]6+, B: [aSyn + 10H]13+, C: [aSyn + 13H]13+ monomer species and for D: [(aSyn)2 + 13H]
13+, and E:
[(aSyn)2 + 17H]
17+, dimer species. The data presented was recorded with 35 V across the drift cell.
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The CCSD at t = 0 for the dimer, [(aSyn)2 + 13H]
13+ is broad,
similar to those exhibited for highly charged monomeric
species. The ATD provides a CCS of ∼3000 Å2 (Fig. 3Di). There
is a small shoulder (∼3600 Å2), which becomes more intense
at Day 3 and is present at Day 5 (Fig. 3Dii–iii). The shoulder is
obscured on the [(aSyn)2 + 13H]
13+ Day 5 CCSD (Fig. 3Diii) by
the broadening of the initial peak (∼3000 Å2). For the higher
charged dimer [(aSyn)2 + 17H]
17+ at t = 0, the CCSD observed is
again broad and centred on ∼3900 Å2 with a shoulder centred
on ∼3200 Å2 (Fig. 3Ei). This CCSD highlights the variability in
the populations in the sample, the large error bars which are
present across the CCSD suggesting several lowly populated
conformationally dynamic species.
These species were chosen as they represent the breadth of
the CSD, remain present throughout the time course, and rep-
resent the multimodal distribution present (ESI† Fig. S3). They
are representative of the CCSD of all observed species from 7 <
z < 22 (data not shown). The large spread in CCS over the
entire CSD, ΔCCS ∼ 1600 Å2 (See Fig. 3Ai and Ci) and the large
spread in CCS for each charge state (Fig. 3A–E) suggests the
protein is flexible in solution and can adopt multiple confor-
mations in solution and gas phase. The average CCS for both
monomers and dimers increases with charge state, which we
attribute to extended, more solvent exposed and therefore
higher protonated forms of the protein in solution an eﬀect
which will be exacerbated by Coulombic repulsion in the gas
phase as reported previously.75 The TEM data of samples sub-
jected to the same solution and environmental conditions,
show no fibrils at t = 0 (ESI† Fig. S2A).
There is a notable lack of change in CCS across the incu-
bation timecourse (Fig. 3) despite the appearance of fibrils in
the solution over the same time (ESI† Fig. S2B). The narrow
CCSD centred on ∼1400 Å2 at t = 0 for [aSyn + 6H]6+, remains
centred on ∼1400 Å2, at t = 3 days and t = 5 days (Fig. 3Ai–iii).
The pattern is repeated for higher charged species, at t = 0 for
[aSyn + 13H]13+ (Fig. 3Ci), the CCSDs is centred on ∼3000 Å2,
and remains so at t = 3 days and t = 5 days (Fig. 3Cii and ii,
respectively). There is also no evidence for narrowing of the
CCSD which would indicate the adoption of a specific confor-
mer. This pattern is also repeated for the dimeric species, see
Fig. 3Ei–iii; the most intense peak remains centred on
∼3900 Å2 and the large error bars of the dimer CCSDs indicate
that α-synuclein remains flexible. This suggests that even fol-
lowing long incubation times, the solution contains confor-
mationally dynamic components, which perhaps exist in rapid
equilibrium between oligomeric species, prior to their seques-
tration into larger oligomers or even fibrils. Such species are
likely to reorganise during the nESI and even the IM experi-
mental timescales, although with time there is less variability,
as evidenced by smaller error bars (Fig. 3ci and iii). A compari-
son of the [aSyn + 6H]6+ monomer and the [(aSyn)2 + 13H]
13+
dimer (Fig. 3) shows no significant decrease in CCS with
dimer formation. The similar number of charges, with respect
to mass, limits any diﬀerence that could be attributed to Cou-
lombic repulsion. This lack of any compaction suggests that
the α-synuclein dimer has a small binding interaction site and
remains a largely unstructured dimer, or the superposition of
many forms. This conclusion concurs with the force spec-
troscopy studies of α-synuclein dimers of Neupane et al.76 who
describe a lack of discrete cooperative unfolding events for
most dimers, indicative of lack of structure. In a small number
of cases ∼15%, they note multiple unfolding transitions,
Fig. 4 CCS distributions of α-synuclein with and without crosslinking. The dashed (Black) line on each CCSD corresponds to the CCSD derived for
each charge state from an un-modiﬁed α-synuclein sample run on the instrument intended for comparison. The solid line on each CCSD corres-
ponds to the CCSD derived for each charge state from a cross linked α-synuclein sample, ordered by increasing number of crosslink modiﬁcations,
(i) 4 modiﬁcations, (ii) 6 modiﬁcations, (iii) 10 modiﬁcations and (iv) 11 modiﬁcations. The number of modiﬁcations relate to the number of crosslinks
present which are a mixture of complete crosslinks and dead end crosslinks. These plots demonstrate the eﬀect of crosslinking and charge state on
the conformational constriction of α-synuclein. All data was taken with 30 V across the drift cell.
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which is supportive of the number of broad conformational
families as well as the day to day variation shown by our MS
and IM-MS experiments.76 The observable monomer and
dimer species, which dominate the mass spectrum possess a
large conformational spread which does not alter significantly
during aggregation. This is despite the evidence from TEM
(ESI† Fig. S1B) that these solutions contain fibrils, suggesting
that the conformations of the soluble feeder stock of the aggre-
gated solution is not altered by it (or at least not that can be
observed by this method), or that the fibrils reversibly dis-
assemble during desolvation. This second explanation is less
likely since the solutions become harder to spray along the
aggregation time course, indicating the presence of aggregates
that block the spray tips.
Crosslinking IM-MS to trap solution phase conformers
Following the use of the cross linking reagent, extensive cross
linking was seen for monomeric α-synuclein as shown in ESI†
Fig. S4. Data for the dimers was not of suﬃcient intensity and
was at too poor resolution to obtain collision cross-section
data due to intensity stealing by the diﬀerent masses of each
cross linked form. CCSDs are derived from the arrival time dis-
tributions for selected charge states following exposure to the
crosslinking reagent are shown in Fig. 4. Analysis of the
CCSDs in Fig. 4 shows three conformational families. The
first, designated C1, is centred at ∼1200 Å2 and is most clearly
visible in the [aSyn + 6H]6+ CCSD (Fig. 4Ai). This compact con-
former is present and remains populous even following the
addition of eleven modifications (Fig. 4Aiv). The second family
of a more extended conformer, E1 is centred at ∼1500 Å2 and
is clearly visible in the [aSyn + 6H]6+ CCSD (Fig. 4Aiii–iv) and
remains present throughout the intervening charge states
([aSyn + 7H]7+ to [aSyn + 9H]9+) to the [aSyn + 10H]10+ (Fig. 4E).
This extended conformer is stabilised by the addition of more
crosslink modifications (See Fig. 4Aiii–iv, [aSyn + 6H]6+ CCSD)
and remains the dominant conformer. This conformational
family matches the Bernstein et al. CCS value for the [aSyn −
8H]8−. The third family, U1 centred at ∼2350 Å2 is most clearly
visible in the [aSyn + 10H]10+ CCSD. This unfolded conformer
is again stabilised by the addition of crosslink modifications,
shown by the gradual defining of the peak in the [aSyn +
10H]10+ CCSD (Fig. 4Ei–iv) and to a smaller extent in the 10
and 11 modification CCSDs of the [aSyn + 9H]9+ charge state
(Fig. 4Diii–iv). The small CCS diﬀerence between [aSyn + 6H]6+
and [aSyn + 10H]10+ is likely to result from the additional cou-
lombic repulsion suﬀered by the [aSyn + 10H]10+ species.
The ability of the crosslinker modification to restrict the
flexibility of the protein can be seen from the narrowing of the
charge state distribution (ESI† Fig. S4). This eﬀect can also be
seen clearly in the CCSD of single charge state for example
that of [aSyn + 7H]7+ (Fig. 4Bi) where narrowing of the CCSD
occurs with the addition of as few as four crosslinking modifi-
cations and more dramatically with eleven (Fig. 4Biv). This nar-
rowing suggests the crosslinks are preventing the protein from
collapsing, preventing the adoption of compact CCS values as
displayed in the unmodified sample (See Fig. 4Biv) in addition
to decreasing the population of conformers sampled. The
same eﬀect is also evident in the CCSDs for other higher
charge states including [aSyn + 8H]8+, however highly charged
species such as [aSyn + 10H]10+, both unmodified and modi-
fied (eleven crosslink modifications, Fig. 4Eiv) exhibit the
same most collapsed state (∼1200 Å2), suggesting coulombic
repulsion is preventing the complete collapse of the protein
which we have previously predicted to be 806 Å2.77 Interest-
ingly, at higher charge states, the crosslinked protein transfers
both compact and extended species (Fig. 4Eiv).
ECD – top down sequencing of an IDP
Here we examine the eﬀect of pH on α-synuclein using ECD-
FT-ICR MS. Although, ECD is a well-established tool for top-
down sequencing of proteins and determination of the posi-
tion of post translational modifications, information on higher
order structure can also be obtained.78 ECD has been pre-
viously applied to α-synuclein to investigate its interaction with
the naturally occurring polyamine, spermine.63,79 Xie et al.79
focussed on [aSyn + 14H]14+, since the fragmentation eﬃciency
is far higher for higher charge states. The FT-ICR MS mass
spectrum is shown in ESI† Fig. S5. Here we examine the frag-
ments from select low charge state monomers, [aSyn + 6H]6+ to
[aSyn + 10H]10+ at pH 6.8 and [aSyn + 7H]7+ to [aSyn + 9H]9+ at
pH 3.5 (Select annotated fragmentation spectra, ESI† Fig. S6–
S9). The fragments from select non-mass coincident dimer
species are also examined, with charge states spanning from
[(aSyn)2 + 13H]
13+ to [(aSyn)2 + 17H]
17+ (Select annotated frag-
mentation spectra, ESI† Fig. S10–S12).
Decreasing the pH from 6.8 to 3.5 led to an increase in frag-
mentation eﬃciency. There is an increase in the intensity of
fragments at pH 3.5 for both monomer and dimer species,
which suggests the protein has adopted a less compact form
with fewer stabilising non-covalent interactions, more suscep-
tible to ECD. This is at variance with reported IM-MS data
which describes the partial collapse of the protein at pH 2.5, a
result of the acidic C-terminus being liable to collapse upon
protonation40 and far-UV CD, FTIR, ANS fluorescence and
SAXS data which demonstrate an increase in structure with a
decrease in pH.72 Although the fragmentation pattern appears
similar, the majority of fragments resolved for the pH 6.8
sample are from the [aSyn + 10H]10+ charge state. This charge
state has been shown via IM-MS to exhibit an extended and
therefore fragmentation-susceptible conformation. The com-
parison of [aSyn + 7H]7+ to [aSyn + 9H]9+ charge states (Fig. 5
and Table 1) for both pHs, highlight the diﬀerence in fragmen-
tation with pH. The increase in fragments seen under low solu-
tion pH conditions could be a result of the extension of the
N-terminus, which has been shown to adopt a more extended
form at low pH, in contrast to the collapse experienced by the
C-terminal region80
For both monomeric and dimeric parent ions, the fragmen-
tation is limited to the N-terminus of the protein, both at pH
6.8 and 3.5. C-terminal fragments are only observed for the
[aSyn + 10H]10+ monomer at pH 6.8 (Fig. 5A). If the α-synuclein
monomers [aSyn + 7H]7+ to [aSyn + 9H]9+ at pH 6.8 and 3.5 are
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considered, no fragmentation is found from Gly47 to Ala140 at
pH 6.8 (Fig. 5A) and between Ala76 to Ala140 at pH 3.5
(Fig. 5B). Similarly, for the α-synuclein dimers, limited C-
terminal fragmentation occurs (Table 1). This data suggests
that under these conditions there is a stable protected core of
the protein involving the C-terminus, this correlates with para-
magnetic relaxation enhancement and NMR dipolar couplings
which demonstrate the presence of long range interactions
between the C-terminus and central region of α-synuclein.81,82
In the case of the dimer, this suggests this may be the region
of the dimer interface, which is supported by findings from
single molecule AFM force spectroscopy measurements.83
However, our results do not correlate with other published
data from CD, FTIR and in-cell NMR35 nor with data from
HDX MS studies,56,58 which suggest independently a C-termini
which is either, protected or unprotected from HDX exchange
due to the presence of secondary or higher structure, high-
lighting the highly dynamic nature of α-synuclein, in particular
the C-terminus.
Discussion and outlook
α-synuclein is known to be an extraordinarily conformational
plastic protein, characteristic of its intrinsically disordered
nature. Our MS data expands on these previous studies, high-
Fig. 5 ECD fragmentation map for α-synuclein monomers at pH 6.8 (top) and pH 3.5 (bottom). Fragmentation eﬃciency is increased at low pH and
increases with charge state.
Table 1 The fragmentation map from α-synuclein dimers where z =
13+, 15+ and 17+ at pH 3.5 and pH 6.8. 13+ fragments are italicized, 15+
fragments are in brackets and 17+ fragments are in bold. Resolution of
the fragment from multiple charge states is identiﬁed by combining the
typography emphasis styles
pH 6.8 pH 3.5
[13+]/(15+)/17+ [13+]/(15+)/17+
C ion Z ion C ion Z ion
(C115) C279 (Z274)
(C57) [C149]
C35 C98
(C6) C75
C50
C47
(C46)
C39
(C38)
C37
C35
C34
(C27)
(C24)
(C23)
(C22)
(C21)
C11
(C9)
(C6)
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lighting the presence of multiple conformational families and
emphasising the susceptibility of α-synuclein to environmental
change, such as pH, as well as highlighting the day to day
variability of our subject. The aggregation of α-synuclein is
strongly linked to the aetiology of Parkinson’s disease; we have
demonstrated the ability of MS to follow in vitro aggregation of
α-synuclein, through the depletion of the solution phase con-
stituents. This method with little modification will allow the
high throughput prototyping of potential aggregation inhibi-
tors, due to the non-discriminatory nature of the technique, a
prerequisite for studying the complex aggregation pathways of
α-synuclein, as previously highlighted by HDX-MS.59 IM-MS
shows a lack of a CCS change with aggregation duration,
suggesting that the species in the solution phase remain
disordered, adopting aggregation related conformational
modifications at the time of sequestration into oligomeric or
fibrillar species. This agrees with the intrinsically disordered
nature of α-synuclein.
The use of gas phase techniques has prompted understand-
able concern as to the biological relevance of these measure-
ments in comparison with solution assays. Here, we have
shown that chemical crosslinking can be used to trap solution
phase species prior to gas phase analysis. Following chemical
crosslinking we have identified three stable conformational
families, compact (∼1200 Å2), extended (∼1500 Å2) and
unfolded (∼2350 Å2) which are also present in the uncross-
linked protein albeit at diﬀering abundances. When we extrap-
olate these values to anticipated Radius of Gyration (Rg) values
from solution (ESI† Fig. S14 and Table S1, we find that these
correlate to 16.8, 26.5, and 54.1 Å, these values compare well
with Rg values calculated for fully globular and random coil
140 amino acid polypeptide chains, of 15.1 Å and 52.1 Å,
respectively and the Rg range established encompasses
reported experimental Rg values.
72 This agreement supports
the use of gas phase techniques on intact proteins as a probe
of solution conformers.
ECD has been established elsewhere as a technique to
probe the location of structure within gas phase protein ions.
The large day to day and sample to sample variability of
α-synuclein even under tight control could explain the increase
in fragmentation eﬃciency that occurs with dropping the solu-
tion pH, a result that contradicts trends observed by multiple
structural techniques. Alternatively, this increased fragmenta-
tion exhibited at low pH may be a result of the remodelling of
α-synuclein. At neutral pH, α-synuclein has been shown to
exhibit compact, intermediate and extended conformers by
our MS, IM-MS and crosslinking IM-MS data and other studies
including Frimpong et al.41 Bernstein et al. identify conformer
collapse at pH 2.5,40 which concurs with measurements from
other biophysical techniques. In line with the work of Frim-
pong et al.41 and Ferreon et al.84,85 scanning through a solu-
tion condition such as pH or SDS concentration enables
access to intermediate conformations of the folding landscape,
in our study the pH was lowered to pH 3.5,40 enabling access
to intermediate conformations such as those identified in ref.
41. The conformational remodelling of α-synuclein has pre-
viously been shown to be substantial, even following small
changes; for example, see the unfolding event between the −8
and −9 charge states in ref. 40. We therefore theorise this
increase in fragmentation is not the result of the low pH dis-
rupting long range interactions which lock α-synuclein in a
semi-flexible state,81,82,86 but rather the induction of large
scale conformational remodelling induced by modifying the
solution environment. This is a similar eﬀect to that seen by
Frimpong et al. via deconvolution of α-synuclein CSDs at
increasing pH,41 prior to protein collapse at lower pH (Bern-
stein et al.40), this intermediate ensemble stage facilitates the
greater fragmentation seen at low pH.
The conformational fluidity of α-synuclein, will and does
slow the progress of our understanding of this system with all
assays. Despite this, MS based techniques can be usefully
applied both to obtain structural information and also to
follow the complex heterogeneous early stages of aggregation
of this amyloidogenic protein.
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